RxDoctor Payments Data

Consuelo Ranninger

Family · Punta Gorda, FLNPI 1053660415

Payments from drug & device makers

$9,956in general payments, 2019–2025

Across 518 payments — averaging $19.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$2K
  • AbbVie$925
  • GSK$847
  • Amgen$736
  • Lilly USA, LLC$715
  • Biohaven Pharmaceuticals, Inc.$517
  • plus $5K from 45 others

What the payments were for

  • Food & beverage$9,86099%
  • Education$961%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$9,956 in reported general payments places this provider in the 95th percentile of 14,618 family providers in Florida.

See all family providers in Florida

Medicare billing

Part B allowed, 2024
$74,743
Medicare patients
413
Services billed
5,640

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OtezlaApremilast33$158,281
OzempicSemaglutide82$141,972
EliquisApixaban115$133,632
Repatha SureclickEvolocumab130$116,932
Trelegy ElliptaFluticasone/Umeclidin/Vilanter73$79,440
JardianceEmpagliflozin55$72,020
RybelsusSemaglutide39$65,491
MounjaroTirzepatide46$51,079
TrulicityDulaglutide36$48,449
FarxigaDapagliflozin Propanediol40$48,097
GemtesaVibegron47$36,996
Breztri AerosphereBudesonide/Glycopyr/Formoterol32$32,854
Tresiba Flextouch U-100Insulin Degludec19$32,055
MyrbetriqMirabegron30$25,312
ProliaDenosumab14$24,419

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$1,602$207,463121 claims
AmgenOtezla, Prolia$736$182,70047 claims
PfizerEliquis$489$133,632115 claims
Lilly USA, LLCMounjaro, Trulicity$715$99,52882 claims
GSKTrelegy Ellipta, Breo Ellipta$847$94,11896 claims
AstraZenecaFarxiga, Breztri Aerosphere$459$80,95172 claims
Sumitomo Pharma America, Inc.Gemtesa$161$36,99647 claims
Astellas Pharma US IncMyrbetriq$147$25,31230 claims
AbbVieLinzess$925$14,20215 claims
MerckLagevrio (Eua)$128$2,78411 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 14,618 family providers in Florida.

Other family in Punta Gorda

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →